Disturbances of the serotoninergic neutrotransmitter system have been implicated in the pathogenesis of mood disorders. A functional polymorphism in the upstream regulatory region of the serotonin transporter gene (5-HTTLPR) has been recently reported to be associated with both unipolar and bipolar disorder. In this study, we investigated the possibility that the 5-HTTLPR might be associated with depressive symptomatology in a sample of mood disorder subjects. One hundred and thirty-two psychiatric inpatients affected by major depressive (n = 67) and bipolar (n = 65) disorder (DSM-IV) were assessed at admission by the Hamilton Depression Rating Scale (HAMD-21, divided into Core, Sleep, Activity, Psychic anxiety, Somatic anxiety and Delusion clusters) and were typed using PCR techniques. The only prior treatment permitted was low dose benzodiazepines (Ͻ5 mg diazepam or equivalent); no prior (Ͻ2 weeks) antidepressant or neuroleptic treatment was allowed. 5-HTTLPR variants were not associated with total depressive symptomatology as measured by HAMD. The short 5-HTTLPR variant was marginally associated with higher psychic anxiety scores (F = 7.11, d.f. = 1,262, P = 0.008). The association was stronger among bipolars and early onset subjects. 5-HTTLPR variants were not associated with the remaining symptom clusters. The upstream regulatory region of the serotonin transporter gene has not, therefore, a major influence on the depressive symptomatology in mood disorder subjects.
Disturbances of the serotoninergic neurotransmitter system have been implicated in the pathogenesis of mood disorders. 1, 2 The serotonin transporter is the major determinant of serotonin inactivation following release at synapses and it is the site of action of SSRI antidepressants. Therefore, the gene coding for the serotonin transporter has been proposed as a candidate for a possible involvement in the pathogenesis of mood disorders, but the primary structure of the serotonin transporter gene was not involved in the pathogenesis of mood disorders. 3 Recently, a polymorphic region containing a 17-bp VNTR in the second intron was found to be associated with unipolar disorder 4 and a functional polymorphism in the upstream regulatory region of the serotonin transporter gene has been associated with both unipolar and bipolar disorder, 5 as well as with anxiety-related traits in normals. 6 This last is a deletion/insertion polymorphism (5-HTTLPR) located at the 5′-flanking regulatory region of serotonin transporter gene on chromosome 17q11.2. It consists of a 44-bp insertion or deletion involving repeat elements 6-8 (from bp −1212 to bp −1255). 6 Heils et al 7 found that the basal activity of the long 5-HTTLPR (l) variant was more than twice that of the short 5-HTTLPR (s) form of the 5-HTTLPR. In particular, 5-HTTLPR l form produced steady-state concentrations of 5-HTT transporter mRNA that were 1.4-1.7 times those in cells containing one or two copies of the 5-HTTLPR s variant and bound 30-40% more of a labeled marker. Uptake of labeled serotonin in cells homozygous for the 5-HTTLPR l form of the promoter polymorphism was 1.9-2.2 times that in cells carrying one or two endogenous copies of the 5-HTTLPR s variant. 6 Taken together, those studies suggest that serotonin transporter gene transcription is modulated by variants of the 5-HTTLPR, with s allele corresponding to low serotonin uptake activity. Moreover, the data associated with the ss and ls genotypes were similar, whereas both differed from the ll genotype, suggesting that the polymorphism has more of a dominant-recessive than a codominantadditive effect.
We previously analyzed 5-HTTLPR, testing a possible association with the symptomatology of major psychoses. [8] [9] [10] No influence of 5-HTTLPR variants on psychopathology as defined by the Operational Criteria for Psychotic Illness (OPCRIT) 11 checklist has been detected. However symptoms other than the ones included in the OPCRIT checklist, such as psychic anxiety, somatic anxiety and hypochondria was not analyzed. Those aspects are of particular relevance as antidepressant drugs with serotonin-modulating activity are effective on anxiety symptoms.
The aim of the present study was to investigate a possible influence of 5-HTTLPR polymorphism on the symptomatology of major depression defined using the Hamilton rating scale for depression (HAMD) 12 in a sample of mood disorder subjects.
5-HTTLPR variants were not associated with the total depressive symptomatology ( Table 1) . Both s allele and s-containing genotypes were marginally associated with higher scores on the psychic anxiety cluster (Table 1) . 5-HTTLPR variants were not associated with the remaining symptom clusters. We repeated the ANOVA considering subgroups homogeneous for diagnosis, age-of-onset (Ͻ25 years) and gender. The association was stronger among bipolars (anxiety score: s = 4.34 vs 1 = 3.42, F = 8.98, d.f. = 1,128, P = 0.003), among early onset subjects (n = 31, anxiety score: s = 4.65 vs 1 = 3.19, F = 11.66, d.f. = 1,60, P = 0.001) and, as a trend, among females (data not shown). Severity of illness may be associated with symptom scores, and it could constitute a stratification bias. So we repeated the ANOVA including indicators of severity as covariate, in turn. We considered the number of depressive episodes and, only for bipolars, of manic episodes, length of disease, presence/absence of delusional features (DMS-IV), duration of index episode and HAMD total score. None of the covariates significantly influenced the results.
Our results indicate that the 5-HTTLPR polymorphism was not associated with total depressive symptomatology in our sample. We also observed a marginal association between both the s allele and the s-containing genotypes and anxiety symptomatology. The association was stronger when considering only bipolar and early onset subjects. This is in accordance with current views of a greater genetic loading in those subjects. 13 Abnormalities in the serotonin system have been described in the pathogenesis of a number of behaviors related to mood disorders. 2 This led to the suggestion that the influence of serotonin would be better analyzed at the level of symptoms rather than syndromes. In fact Lesch et al 6 detected a significant association between the 5-HTTLPR genotype and the Neuroticism factor in normals. Individuals with either one or two copies of the s form had higher Neuroticism scores than did individuals homozygous for the l variant. However conflicting replications followed, with negative findings using both 5-HTTLPR and the 5HTT VNTR, 14 and with a positive association using the 5HTT VNTR. 15 Mood disorders too were not unequivocally associated with both polymorphisms at 5-HTTLPR, 4, 5, 16, 17 and a linkage study on bipolar families using the PstI RFLP at the 5HTT locus did not support the presence of a susceptibility locus for bipolar disorder near the serotinin transporter. 18 Finally, the Tridimensional Personality Questionnaire temperament of harm avoidance did not reveal associations of personality trait in normals with 5-HTTLPR. 19 Our study suggests an involvement of 5-HTTLPR variants in anxiety symptomatology, among mood disorder subjects. Even though the main finding of this paper is an absence of association with total depressive symptomatology, together with our previous reports excluding a 5-HTTLPR influence on symptoms of major psychoses, [8] [9] [10] we may hypothesize a broad effect of 5-HTTLPR variants on anxiety symptomatology both among patients and normals. 6 Moreover both ls and ss genotypes showed similar anxiety scores, in accordance with a putative dominant effect of the variant on the serotonin transporter activity. 6 This association may explain previous conflicting results where anxiety symptomatology was not considered, and a variable rate of anxious subjects may have obscured or emphasized associations vs controls. Indeed, by selecting subjects with anxiety symptom scores one standard deviation above average or more, we observed that the rate of s subjects rises from 0.41 to 0.54.
The power of our sample was enough to detect a standardized difference (effect size) up to d = 0.35 (depending on the frequency of the 5-HTTLPR risk allele, considering a power of 0.8 and alpha Ͻ0.05 twotailed), that corresponds to a difference of 0.8 points on the anxiety HAMD cluster score. Therefore our sample had sufficient power to detect the observed association. The variance explained by the s allele on the anxiety factor is about 2%, 20 which is in accordance with current theories of polygenic inheritance in psychiatric disorders. 21, 22 Our sample is composed mainly by severe inpatients as evidenced by a number of severity indicators like total HAMD scores, number of episodes and the rate of psychotic symptoms. This should indeed be considered a selection bias, probably due to the fact that our center is a tertiary care setting. On the other hand the selection of severe subjects should guarantee against the possible inclusion of phenocopies. 13 A limitation of the present study is the cross-sectional approach, where we employed single time-point prevalence to rate depressive symptoms, which may not correspond to a lifetime perspective. However, we scored subjects at index episode that correspond to a major depressive episode requiring hospitalization, and follow-up studies evidenced that episodes are substantially stable over time both as for subtype and severity. 23 Anyway, we cannot exclude future symptom fluctuations. Another limitation might be related to effects of drug treatments, but we specifically allowed only low doses of benzodiazepines (flurazepam 15-30 mg), with no antidepressant or neuroleptic treatments for at least 2 weeks. Moreover, the low doses of benzodiazepines were administered to virtually all subjects (95%) and only at bedtime. Ethnic origin is frequently a cause of stratification bias but our sample was composed of subjects with Italian antecedents for at least two generations; though genetic heterogeneity has been evidenced for some isolated populations, 24 Italy is characterized by a substantial genetic homogeneity. 25, 26 Most studies, including the present, use multiple statistical testing. Therefore, significance levels would be unlikely to survive correction in many cases. Indeed, we corrected for the six HAMD factors and part of our results survived this correction. However, for analyses of candidate genes that have high a priori probabilities of association, multiple correction could not represent the best choice. 27, 28 Replication using independent samples should be considered a more suitable strategy.
Since the serotonin transporter is the major determinant of serotonin inactivation following release at synapses and it is the site of action of SSRI antidepressants, its activity should be better analyzed evaluating response to SSRI antidepressants. In fact, while longterm adaptations may intervene among individuals with the 5-HTTLPR short variant preventing any abnormal depressive symptomatology, during the rapid neurotransmitter changes while under antidepressant treatment, s individuals may show an impaired response to antidepressants. Our group is currently testing this hypothesis. In conclusion, 5-HTTLPR was marginally associated with psychic anxiety symptomatology in mood disorders; neither the remaining symptom clusters nor the total HAMD score were associated with 5-HTTLPR variants.
Materials and methods

Sample
One hundred and thirty-two psychiatric inpatients (age = 48.14 ± 13.26 years; age-of-onset = 34.74 ± 11.82 years; males 34.1%; education = 9.36 ± 3.95 years; duration of index epidode at admission = 16.7 ± 20.0 weeks) consecutively admitted to the Department of Neuropsychiatry at the Institute H San Raffaele (DSNP-HSR), were included in this study. Thirty-eight subjects are overlapping with a larger sample tested for a possible interaction between the dopamine receptor D4 gene and 5-HTTLPR on psychotic symptomatology and with a mood disorder sample scored by the OPCRIT checklist. 8, 10 Patients were evaluated using the SADS 29 and/or OPCRIT checklist. 11 Lifetime diagnoses were assigned by two independent psychiatrists on the basis of interviews and medical records, according to DSM-IV criteria. 30 The Hamilton Depression Rating Scale (HAMD- 21) 12 was administered at admission prior to treatment by a trained psychiatrist and supervised by a senior psychiatrist both blind to genetic data. Criteria for inclusion in the study were: major depressive disorder, not including dysthymia (n = 67; age = 47.31 ± 13.09; onset = 35.66 ± 12.00; males 28.4%; No. depressive episodes = 4.53 ± 6.12; delusional subjects 38.8%) and bipolar disorder, not including cyclothymia (n = 65; age = 49.0 ± 13.49; onset = 33.78 ± 11.65; males 40.0%; No. manic episodes = 2.23 ± 2.35; No. depressive episodes = 4.23 ± 2.87; delusional subjects 54.7%). The presence of concomitant diagnoses of mental retardation or drug dependence, together with somatic or neurological illnesses that impaired psychiatric evaluation (eg hypothyroidism mimicking a depressive state) represented exclusion criteria. The only prior treatment permitted was low dose benzodiazepines (Ͻ5 mg diazepam or equivalent); no prior (Ͻ2 weeks) antidepressant or neuroleptic treatment was allowed. Informed consent was obtained from all probands, who were unrelated and of Italian descent with antecedents from all parts of the country.
DNA analysis
DNA was extracted from leucocytes by NaCl precipatation. 31 For PCR forward 5′-GGCGTTGCCGCT CTGAATGC-3′ and reverse 5′-GAGGGACTGAGCTGGA CAACCAC-3′ primers were employed. Thirty-five cycles of 1 min at 95°C, 1 min at 61°C and 1 min at 72°C were performed. The assay mix contained in a volume of 30 l 50 ng genomic DNA, 2.5 mM dNTPs, 0.1 g of sense and antisense primer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 5% DMSO and 1 U Taq Polymerase. PCR products were separated on 3% agarose gels supplemented with ethidium bromide allowing differentiation of the long (528 bp) and the short (484 bp) variant.
Statistical analysis
Differences were assessed by one-way Analysis of Variance (ANOVA) and Analysis of Covariance (ANCOVA) when including covariates. Frequencies were compared by Chi-square test. Alpha values were considered significant when below 0.008 (0.05 / 6 HAMD factors). HAMD items were pooled into the following factors: Core (items 1, 2, 7, 8, 10, 13), Sleep (items 4, 5, 6), Activity (items 7, 8), Psychic anxiety (items 9, 10), Somatic anxiety (items 11, 12, 13), Delusion (items 2, 15, 20) . [32] [33] [34] [35] [36] [37] The power of our sample for detecting differences amongst 5-HTTLPR variants was calculated considering an alpha value of 5% two-tailed. With these parameters in our sample we had a high power (0.80) to detect a medium-small effect size (0.35) that corresponded to a difference of approximately 2.1 points between the two alleles on the total HAMD. 20 
